Sandan, I really don't mind questions or varying points of view at all. But some of the questions just can't be answered right now. I've asked Mr. Schneiderman a few questions about RapiMeds and his reply was, "I can't reply at this time news will follow". I'm find with that. I let the man do his job. As to varying points of view, I welcome it. And, being a proud member of the CORE, I do allow a lot of latitude. However, when people get nasty and start tearing down a stock I believe in and individuals I respect, they will hear back from me. I have been playing the penny stocks now for near three years and can say I have done quite well. Oh, I've also lost on a few real losers as well. But, I picked SCRC to be a winner and I know it will be. I've been in the pharma industry for 37 years and I've seen company's business plans change mid stream on several occasions, just like we saw with compounding and SCRC. Mr. Schneiderman's decision to explore and develop compounding as a revenue steam has been brilliant. And I know RapiMeds are still alive and well, it's just taking longer to develop than we all thought. All the revenue streams he eluded to on his interview will soon pay off and we the investors will be the beneficiaries of this success.
Sandan, I really don't mind questions or varying points of
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Biogen's Stock Hits Yearly Low: Market Trends and Analyst Insights
Biogen's Current Stock Performance Biogen Idec Inc (NASDAQ: BIIB) is experiencing a significant downturn, recently reaching a 52-week low of $144.96. This predicament is attributed to various market pressures and internal challenges affecting the biotechnology sector. With a current market capitalization of approximately $21.2 billion, the company has faced mounting...
Continue Reading
Dana Incorporated Welcomes Nora LaFreniere to Board of Directors
Dana Incorporated Appoints Nora LaFreniere to the Board Dana Incorporated (NYSE: DAN) recently announced the addition of Nora LaFreniere to its board of directors, effective immediately. This decision marks an important step for Dana as it continues to focus on strategic growth and innovation in the mobility solutions sector. Professional Background of Nora LaFreniere...
Continue Reading
On Holding AG: Riding the Wave of Growth and Innovation
On Holding AG Thrives with Strategic Growth Initiatives On Holding AG (NYSE: ONON) has witnessed an impressive surge of nearly 20% recently, showcasing its astonishing performance in the sneaker market. The latest earnings report reveals that the Swiss sneaker manufacturer is not just maintaining its position but is actively exceeding the competition from major players...
Continue Reading
Citizens Bank to Redeem Senior Notes, Enhancing Financial Strategy
Citizens Bank Announces Redemption of Senior Notes Citizens Bank, N.A. has made an important announcement regarding the redemption of its Senior Notes. This strategic move involves all of the bank's outstanding 6.064% Fixed/Floating Rate Senior Notes, amounting to a significant total of $600,000,000. The redemption price will correspond to 100% of the principal amount of...
Continue Reading
Impressive Financial Growth in VitalHub's Q3 Report
Overview of VitalHub's Q3 Performance VitalHub Corp. reported significant financial achievements for the third quarter of 2025. The company's Annual Recurring Revenue (ARR) saw a remarkable growth of 75% from the previous year, reaching $93.7 million. Alongside this, total revenue surged by 94% year-over-year, amounting to an impressive $32.0 million. Adjusted Earnings...
Continue Reading